{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:01:46Z","timestamp":1793235706125,"version":"4.5.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Erythematotelangiectatic rosacea (ETR) lacks a gold-standard treatment. Recent studies show that intradermal Botulinum Toxin-A (BoNT-A) is effective for erythema, though objective data are limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>This study aims to evaluate the efficacy and tolerability of intradermal BoNT-A in patients with ETR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>In this randomized, double-blind, split-face study, 30 patients were enrolled. One side of the face received 15 units of BoNT-A, reconstituted in 10 mL of saline, while the control side received saline injections. Assessments were made at baseline and 1-month posttreatment. Clinician's Erythema Assessment (CEA) scale and Patient Self-Assessment (PSA) scores were recorded. Erythema and Melanin Index measurements using a Mexameter. Background erythema was assessed through dermatoscopy, while vascular structure and density were evaluated using Investigative Global Assessment (IGA) scores through videocapillaroscopy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>The BoNT-A-treated side demonstrated significant reductions in CEA scores, Erythema Index, and dermatoscopic background erythema, while no significant changes were observed on the saline control side. IGA scores indicated a significant response to treatment on the BoNT-A side. Patient Self-Assessment scores improved on both sides. No serious adverse events requiring hospitalization were reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Intradermal BoNT-A effectively reduces erythema and vascular density in patients with ETR and is well-tolerated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000004528","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T13:05:04Z","timestamp":1734354304000},"page":"515-521","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Effects of Botulinum Toxin Type A Treatment on Clinical and Biophysical Parameters in Patients With Erythematotelangiectatic Rosacea: A Prospective, Randomized, Controlled, Double-Blind Study"],"prefix":"10.1097","volume":"51","author":[{"given":"Bu\u011fra Bur\u00e7","family":"Da\u011fta\u015f","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan","family":"Erdem","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medeniyet University Hospital, Istanbul, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011fba \u0130lter","family":"G\u00fcne\u00e7","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Bal","family":"Avc\u0131","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bayburt State Hospital, Bayburt, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vildan","family":"Manav","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe Esra","family":"Koku Aksu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"R1-20250425","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2004.03.030","article-title":"Rosacea: I. Etiology, pathogenesis, and subtype classification","volume":"51","author":"Crawford","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R2-20250425","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2017.08.037","article-title":"Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee","volume":"78","author":"Gallo","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R3-20250425","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/365160a0","article-title":"Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25","volume":"365","author":"Blasi","year":"1993","journal-title":"Nature"},{"key":"R4-20250425","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/toxins12050332","article-title":"FDA approvals and Consensus guidelines for botulinum toxins in the treatment of dystonia","volume":"12","author":"Spiegel","year":"2020","journal-title":"Toxins (Basel)"},{"key":"R5-20250425","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/jocd.15962","article-title":"Treating rosacea with botulism toxin: protocol for a systematic review and meta-analysis","volume":"23","author":"He","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"R6-20250425","first-page":"e76","article-title":"A new treatment regimen for rosacea: onabotulinumtoxinA","volume":"11","author":"Dayan","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"suppl 1","key":"R7-20250425","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/DSS.0000000000000277","article-title":"Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea","volume":"41","author":"Bloom","year":"2015","journal-title":"Dermatol Surg"},{"key":"R8-20250425","doi-asserted-by":"crossref","first-page":"688","DOI":"10.5021\/ad.2018.30.6.688","article-title":"A pilot study to evaluate the efficacy and safety of treatment with botulinum toxin in patients with recalcitrant and persistent erythematotelangiectatic rosacea","volume":"30","author":"Park","year":"2018","journal-title":"Ann Dermatol"},{"key":"R9-20250425","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/DSS.0000000000001819","article-title":"Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double-blind, placebo-controlled, split-face pilot study in rosacea patients with facial erythema","volume":"45","author":"Kim","year":"2019","journal-title":"Dermatol Surg"},{"key":"R10-20250425","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm1616","article-title":"Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea","volume":"13","author":"Yamasaki","year":"2007","journal-title":"Nat Med"},{"key":"R11-20250425","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/jid.2014.222","article-title":"Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea","volume":"134","author":"Muto","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R12-20250425","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdermsci.2018.12.004","article-title":"Botulinum toxin blocks mast cells and prevents rosacea like inflammation","volume":"93","author":"Choi","year":"2019","journal-title":"J Dermatol Sci"},{"issue":"6 suppl 1","key":"R13-20250425","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaad.2013.04.045","article-title":"New insights into rosacea pathophysiology: a review of recent findings","volume":"69","author":"Steinhoff","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R14-20250425","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/jid.2011.424","article-title":"Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea","volume":"132","author":"Sulk","year":"2012","journal-title":"J Invest Dermatol"},{"key":"R15-20250425","doi-asserted-by":"crossref","first-page":"3853754","DOI":"10.1155\/2016\/3853754","article-title":"The efficacy and safety of fractional CO\u2082 laser combined with topical type A botulinum toxin for facial rejuvenation: a randomized controlled split-face study","volume":"2016","author":"Zhu","year":"2016","journal-title":"Biomed Res Int"},{"key":"R16-20250425","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nbd.2012.07.010","article-title":"Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A","volume":"48","author":"Shimizu","year":"2012","journal-title":"Neurobiol Dis"},{"key":"R17-20250425","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3390\/toxins7072659","article-title":"Treatment of chronic migraine with OnabotulinumtoxinA: mode of action, efficacy and safety","volume":"7","author":"Szok","year":"2015","journal-title":"Toxins (Basel)"},{"key":"R18-20250425","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1172\/JCI30142","article-title":"Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism","volume":"117","author":"Schauber","year":"2007","journal-title":"J Clin Invest"},{"key":"R19-20250425","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/iwj.13673","article-title":"Safety and efficacy of botulinum toxin type A in preventing and treating scars in animal models: a systematic review and meta-analysis","volume":"19","author":"Pan","year":"2022","journal-title":"Int Wound J"},{"key":"R20-20250425","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1097\/GOX.0000000000000852","article-title":"Botulinum toxin A: dose-dependent effect on reepithelialization and angiogenesis","volume":"4","author":"Gugerell","year":"2016","journal-title":"Plast Reconstr Surg Glob Open"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T01:00:39Z","timestamp":1745542839000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004528","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]}}}